Carbetocin Side Effects: Safety Signals and Warnings
Carbetocin safety concerns are compound-specific. The main listed side effects are Abdominal pain, Nausea, and Flushing. The main warning signals are Not recommended for use during pregnancy or for labor induction, Caution in patients with pre-eclampsia or cardiovascular disease, and Not recommended for repeated dosing - single-dose use only.
Direct Answer
Carbetocin (Duratocin) is approved in Canada, Europe, and other markets for postpartum hemorrhage prevention following cesarean delivery, with Phase 3 data from the WHO CHAMPION trial confirming non-inferiority to oxytocin. It is not FDA-approved in the US. Its longer duration of action (4-7 hours vs. minutes for oxytocin) is its clinical differentiator. A legitimate approved drug in its specific obstetric niche.
- Evidence grade
- Level B
- Research status
- Approved Outside US
- Category
- Sexual Health
- Evidence context
- Postpartum hemorrhage prevention (cesarean delivery), long-acting oxytocin receptor agonist research
Reported Side Effects
- Abdominal pain
- Nausea
- Flushing
- Headache
- Tremor
- Hypotension
- Pruritus
- Metallic taste
Warnings
- Not recommended for use during pregnancy or for labor induction
- Caution in patients with pre-eclampsia or cardiovascular disease
- Not recommended for repeated dosing - single-dose use only
- Hepatic and renal impairment may affect clearance
Known or Plausible Interactions
- Prostaglandins (additive uterotonic effect - use with caution)
- Ergot alkaloids (ergometrine - potential additive vasoconstrictive effects)
- Epidural anesthetics (may enhance hypotensive effect)
Regulatory Context
Approved in more than 30 countries, including Canada and European markets, for postpartum-hemorrhage prevention. It is not FDA-approved in the United States. Heat-stable carbetocin is included on the WHO Model List of Essential Medicines.
Evidence Snapshot
| Evidence grade | Level B |
|---|---|
| Research status | Approved Outside US |
| Best supported outcomes | Postpartum Hemorrhage Prevention (Level A), Reduced Need for Additional Uterotonics (Level B), and Uterine Tone Maintenance (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-08-27 |
Quick Answers
What are the side effects of Carbetocin?
Carbetocin safety concerns are compound-specific. The main listed side effects are Abdominal pain, Nausea, and Flushing. The main warning signals are Not recommended for use during pregnancy or for labor induction, Caution in patients with pre-eclampsia or cardiovascular disease, and Not recommended for repeated dosing - single-dose use only.
What is the evidence level for Carbetocin?
Carbetocin is rated Level B. Its current research status is Approved Outside US.
What is Carbetocin best known for?
Postpartum hemorrhage prevention (cesarean delivery), long-acting oxytocin receptor agonist research.
Where can I read the full Carbetocin evidence review?
The full evidence review is available at https://examinepeptides.com/library/carbetocin.
Related Guides
How to Cite This Page
ExaminePeptides. "Carbetocin Side Effects: Safety Signals and Warnings." Last reviewed 2026-08-27. https://examinepeptides.com/answers/carbetocin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.